ADPT Adaptive Biotechnologies Corp

P/E --
Forward P/E --
Price/Sales 12.07
Beta 2.072
Div Yield --
Market Cap --

Company Analysis

Latest News

Adaptive Biotechnologies Splits in Two and Borrows $250 Million — Is This a Cleanup or a Fire Sale?

Adaptive Biotechnologies Splits in Two and Borrows $250 Million — Is This a Cleanup or a Fire Sale?

Shares of Adaptive Biotechnologies sank 7.2% to $16.20 in pre-market trading after the company unveiled a double-barreled announcement late Sunday: it will...

🔴 Adaptive Biotechnologies Corp is trading 7.2% down today after business separation and $250M convertible notes offering

Adaptive Biotechnologies Corp is trading 7.2% down at $16.20 in pre-market trading after announcing a strategic business separation and a $250 million...

Adaptive Biotechnologies Announces Business Separation and $250M Convertible Notes Offering

Adaptive Biotechnologies announced a plan to separate its Minimal Residual Disease (MRD) and Immune Medicine businesses to allow each segment to pursue...

🔴 Adaptive Biotechnologies Corp is down 9.5% today following Convertible Senior Notes Offering and Plan to Separate Businesses

Adaptive Biotechnologies Corp. is trading 9.5% down at $15.81 in after-hours trading after announcing a proposed offering of $250 million in convertible senior...

🔴 Adaptive Biotechnologies Corp extends move to 5.0% down

ADPT is trading at $17.79, down 5.0% versus the comparison close of $18.73 during regular trading. This is a price-movement alert; no separate company-specific...

🔴 Adaptive Biotechnologies Corp is trading 4.2% down today on profit-taking after a multi-day rally on positive clonoSEQ data

Adaptive Biotechnologies Corp is trading at $17.95, down 4.2% today as the stock undergoes consolidation following a significant multi-day rally. • The recent...

🟢 Adaptive Biotechnologies Corp is trading 6.7% up today, rallying on positive clinical data and outlook

Adaptive Biotechnologies Corp is trading 6.7% higher at $19.99 in pre-market, extending a rally driven by positive company developments. • The surge follows...